Pharmacies in the Balearic Islands continue to experience difficulties in supplying essential treatments due to the lack of medicines -especially digestive enzymes, antidepressants and antibiotics- according to data from the LUDA Partners network, corroborated by the Official College of Pharmacists of the Balearic Islands (COFIB).
Among the most affected drugs are digestive enzymes, with Kreon as the main example. All its presentations maintain supply incidents at national level. The AEMPS has activated exceptional measures to ensure that patients can access the treatment, including dispensing through the Medicines Service in Special Situations, according to Diario de Mallorca.
The shortage also affects antidepressants, with Anafranil among the most difficult to find, and some antibiotics, especially Furantoin. In addition, there are problems in dermatological products such as Daktarin or Lamisil. In the last month alone, LUDA Partners detected 2,784 presentations with supply problems in Spain, which shows the magnitude of the phenomenon.
Despite this, COFIB confirms that the situation has improved compared to recent years. The AEMPS records a 15% decrease in incidents between 2024 and 2025, and a 22% decrease compared to the peak reached in 2023. In the Balearic Islands, coordination between pharmacies -through tools such as FarmaHelp- resolved more than 68% of the requests for medicines located in other establishments.
According to experts, the problem of shortages has structural causes that will not be solved in the shortterm: delocalization of production outside the EU, global logistical tensions, increased demand and regulatory constraints. While Europe works to strengthen pharmaceutical autonomy, Balearic pharmacies continue to resort to search systems and AEMPS contingency measures to avoid the interruption of essential treatments.
